OPEN ACCESS

Saudi Journal of Medical and Pharmaceutical Sciences
Abbreviated Key Title: Saudi J Med Pharm Sci
ISSN 2413-4929 (Print) | ISSN 2413-4910 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Original Research Article **Endocrinology**

Outcomes of Gestational Diabetes in Newborns

Najeeb Ullah[1], Professor Abulikemu Tuerdi[2*], Yasen Mijiti[3], Doctor Sadia Hassan[4], Syed Muhammad Ali[5], Rabiyyah Bashir[6]

[1]Master Student of Xinjiang Medical University, Department of Endocrinology, Xinyi Road, Urumqi, Xinjiang, China
[2]Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Xinyi Road, Urumqi, Xinjiang, PR China
[3]Dean of International College of Xinjiang Medical University, Xinyi Road, Urumqi, Xinjiang, China
[4]Department of General Surgery, DHQ Hospital Hunza, Hunza, Gilgit, Pakistan
[5]Master Student of Xinjiang Medical University, Department of Nephrology, Xinyi Road, Urumqi, Xinjiang, China
[6]Post Graduate Trainee, Bahria International Hospital, Islamabad, Pakistan

DOI: 10.36348/sjmps.2024.v10i02.011 | **Received:** 13.01.2024 | **Accepted:** 21.02.2024 | **Published:** 24.02.2024

***Corresponding author:** Professor Abulikemu Tuerdi
Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Xinyi Road, Urumqi, Xinjiang, PR China

Abstract

With the rising trend in obesity, the incidence of gestational diabetes mellitus (GDM) and perinatal complications associated with the condition are also on the rise. Since the early 1900s, much knowledge has been gained about the diagnosis, implications, and management of gestational diabetes with improved outcomes for the mother and fetus. Worldwide, there is variation in the definition of GDM, methods to screen for the condition, and management options. The International Association of Diabetes in Pregnancy Study Groups has published recommendations for a one-step approach to screen pregnant women for GDM, in order to develop outcome-based criteria that can be used internationally. However, management of GDM continues to be varied, and currently several options are available for treatment of hyperglycemia during pregnancy. A review of various aspects of GDM is discussed with a focus on the medical management during pregnancy, as practiced in the United States.

Keywords: Gestational diabetes, Newborns, Diabetes in pregnancy.

INTRODUCTION

One of the most common metabolic diseases during pregnancy is gestational diabetes mellitus (GDM), which can cause issues with the mother's and the child's health [1]. Pregnancy-related diabetes was originally documented by German physician Bennewitz in 1824 [2]. Williams proposed physiological and pathophysiological thresholds for "transient glycosuria in pregnancy" in 1909, what is possibly the first description of diagnostic criteria for diabetes in pregnancy in the United States [3]. New diagnostic criteria were recommended by the International Association of the Diabetes and Pregnancy Study Group (IADPSG) in 2010 [4], drawing on the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study. Gestational diabetes may result when adaptive β-cell hyper functionality during pregnancy is unable to offset maternal insulin resistance due to placental synthesis of diabetogenic substances, such as human placental lactogen, in late pregnancy [6, 7].

Pre-pregnancy diabetes is not included in the definition of gestational diabetes. The incidence of GDM is 3-6%, and it often manifests after 20–24 weeks of pregnancy, according to statistics [5]. It is a common, high-risk metabolic issue. Women who have gestational diabetes are more likely to experience unfavorable pregnancy outcomes. Globally, studies indicate that 7–10% of pregnancies are affected with GDM [8-11]. The prevalence of several risk variables in the community, such as maternal age and BMI, the prevalence of diabetes, and the ethnicity of women, causes rates to differ between research [12]. Over the past several decades, GDM prevalence has increased globally [13]. In 2017, the International Diabetes Federation (IDF) reported that 14% of people worldwide have GDM, with rates as high as 9% in Africa, 12.6% in North America, and 21% in Asia. [14].

Pregnant women without a history of diabetes may develop gestational diabetes mellitus (GDM), characterized by elevated blood glucose levels. Human placental lactogen and prolactin stimulate pancreatic B-

cell hyperplasia during a normal pregnancy, raising insulin levels. Insulin resistance increases as a result of placental release of diabetogenic hormones like progesterone, growth hormone, corticotropin-releasing hormone, and placental lactogen. GDM results from an inability to overcome pregnancy-induced insulin resistance in spite of B-cell hyperplasia. Preeclampsia, delivery weights greater than 4,000 grams, and shoulder dystocia are among the elevated hazards associated with GDM for both the mother and the newborn. As a result, managing and diagnosing GDM is critical [15].



One of the most typical pregnancy problems is gestational diabetes mellitus [16]. Complications from GDM include preeclampsia, macrosomia, preterm birth, hypoxia, and hypoglycemia, which can affect both mothers and newborns [17]. Large for gestational age (LGA) births, defined as birth weights > than the 90th percentile for a given gestational age or ±2 SD from the normal average for gestational age, sex, and race, are more common in pregnant women with GDM [18].

METHODS

Using the PubMed and Google Scholar databases, a thorough search was conducted for pertinent systematic reviews and publications. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards are followed in this review. The years of publishing varied from 1987 to as well as 2023. Also, by tracking the citations of the papers that were retrieved, more pertinent articles were found using Google Scholar. The study's main concept and the associated references are depicted in the upper graphic.

DISCUSSION

Diagnostic Criteria

The human body experiences "hormonal challenges" during pregnancy. Insulin resistance is facilitated by placental hormones such progesterone, estrogen, and placental lactogen, which are necessary to ensure a sufficient supply of nutrients for the developing child [19]. When a mother's pancreatic insulin supply is insufficient to counteract insulin resistance and control the level of hyperglycemia, gestational diabetes mellitus (GDM) results. The main risk factor is B-cell malfunction, which can be brought on by autoimmune or monogenic processes, develops in the context of preexisting chronic insulin resistance (obesity, ethnicity, and polycystic ovarian syndrome [PCOS]), or both [20]. The diagnostic standards and treatment strategy of Reduced perinatal outcomes and identification of women at risk for type 2 diabetes mellitus were the goals of pregnancies complicated by GDM. The HAPO study found that there was no obvious "cut-off" in the relationship between maternal hyperglycemia, poor perinatal outcomes, and neonatal obesity [21]. The 2-hour, 75-gram oral glucose tolerance test (OGTT) at 24–28 weeks of gestation has been accepted as the best

screening test for gestational diabetes mellitus (GDM) by the World Health Organization (WHO), the Endocrine Society, the Australian Diabetes in Pregnancy Society (ADIPS), the International Federation of Gynecology and Obstetrics (FIGO), the European Association for the Study of Diabetes (EASD), and the European Board and College of Obstetrics and Gynecology (EBCOG). The current screening guidelines are based on observational research, and there is no proof that utilizing these diagnostic "cut-off points" can improve the negative long-term effects. Furthermore, the generalizability of these rules is called into question by distinct ethnic traits, infrastructure, and financial resources.

Consequences:

The risk of endometrial, urinary tract, and wound infections in mothers is increased in pregnancies complicated by diabetes when there is inadequate glycemic control [22]. Although the precise mechanism is not fully understood, insulin resistance appears to be a major contributing component. Independent of birth weight, the diagnosis and treatment of GDM lowers the threshold for cesarean sections (CS), the preferred mode of delivery [23]. Mothers with gestational diabetes mellitus (GDM) are at least ten times more likely to develop type 2 diabetes in the future, with a higher prevalence over the first five years. Additionally, they are twice as likely to develop hypertension and coronary artery disease [24]. Hemoglobin becomes glycosylated as a result of persistent maternal hyperglycemia, which lowers its ability to deliver oxygen. Anaerobic metabolism increases lactate generation and acidemia in the event that the fetal adoptive mechanisms are unable to counteract the hypoxemia, which can lead to intrauterine death. Infant anthropometry and lung maturation are negatively impacted by fetal hyperinsulinemia. Neonatal respiratory distress syndrome results from an environment that is hyper insulinemic, which suppresses the production of cortisol and surfactant protein A/B [25]. Obesity and metabolic dysfunction in the future are associated with gestational diabetes. Maternal hyperglycemia has been related to lower insulin sensitivity by the age of 14 years, elevated HbA1c, impaired glucose tolerance, and impaired fasting glucose, according to research from the HAPO cohort [26, 27].

The most significant therapies in the management of GDM are lifestyle modifications since they usually result in appropriate control. It is recommended that expectant mothers maintain a well-balanced diet specific to their needs. General suggestions include limiting carbohydrates to no more than 40% of daily calories and choosing meals with low glycemic index. Target weight growth for the GDM group should be set 10% lower than that of a typical pregnancy, yet in cases of extreme obesity, it's generally reasonable to limit total weight gain to less than 5 kg [28]. Since they can result in fetal malnutrition and prenatal development retardation, maternal hunger and weight loss are generally discouraged [29] quent exercise helps people with GDM because it improves skeletal muscle glucose absorption and insulin sensitivity. It is recommended that pregnant women engage in mild-to-moderate exercise for 150 minutes per week. Capillary blood glucose self-monitoring gives information on appropriate glycemic control but may also highlight the need for more urgent medical attention. Every expert committee recommends tracking fasting and 1 or 2 hour postprandial glucose measurements every day, with the goal of keeping levels below 95 (5.3 mmol/L), 140 (7.8 mmol/L), and 115 mg/dL (6.4 mmol/L), in that order [30].

When lifestyle modifications are not enough to meet treatment goals, a medical strategy is needed. The choices include oral antidiabetic medications and injectable insulin. The benefits of taking medication during pregnancy should exceed any possible hazards, and the safety of the mother and fetus should be taken into account. With an instant impact on maternal glycemia, insulin therapy is often regarded as the safest approach for treating GDM. Human insulins do not cause problems for the fetus and do not cross the placenta [31] Tight glycemic control can result from insulin therapy, but since hypoglycemia episodes are linked to problems with growth and development, care must be taken to prevent them. In the third trimester, recurring occurrences could be a sign of placental insufficiency [32] Additionally, mothers who receive insulin gain more weight than those who receive metformin. Although metformin is more well-tolerated by patients, it is linked to higher chances of treatment failure; most women need to add insulin in order to attain normoglycemia [33].

Oral antidiabetics are recommended by expert committees from England, Scotland, and New Zealand as the first-line pharmacological treatment for diabetes, while the Canadian and American Associations state that metformin and/or glibenclamide should only be given to women who refuse insulin after being informed of the "off-label use." FIGO and Gol view insulin and oral antidiabetics as safe and effective choices for managing gestational diabetes mellitus (GDM) beyond 20 weeks of pregnancy. However, because oral medicines have a high failure rate, insulin is advised as the first-line treatment for hyperglycemia throughout the first trimester.

Antinatal Care:

A thorough fetal anatomy scan, which includes a heart examination, should be carried out between weeks 18 and 20 of pregnancy in women who are diagnosed with GDM before 20 weeks. When gestational diabetes mellitus is diagnosed, women should go to antenatal clinics every two weeks or once a month at the latest. Glycemic management, proteinuria, maternal blood pressure, lifestyle modifications, and other obstetric problems should all be discussed during each appointment. Every four weeks after the first one at 28

weeks of pregnancy, growth scans should be carried out. The period between growth scans should be shortened to two weeks if there is fetal macrosomia or polyhydramnios. The risk of stillbirth increases with gestational diabetes mellitus (GDM) in pregnancies that last between 36 and 39 weeks; the relative risk ranges from 1.45 to 1.84 [34]. When medical resources and access to assessment units are unavailable, a substitute is the Daily Fetal Activity Assessment, which requires the fetus to kick at least ten times within two hours following a meal. To ensure fetal lung maturity, any women who are at risk of elective caesarean section before 39 weeks of gestation or vaginal delivery between 24 and 36 weeks of gestation should take steroids. The recommended steroid regimen consists of two intramuscular doses of betamethasone 6 mg spaced 12 hours apart. After the second steroid dose, glucose levels should rise for up to five days [35], and insulin needs should climb by 40% in the first two days.

Intrapartam Care:

Due to variances in the kind and severity of diabetes, beta cell reserve, and degree of insulin resistance, each woman's diabetic care strategy throughout birth should be unique. Sadly, there isn't a recommended best practice for achieving normoglycemia intrapartum because there aren't enough well-designed, adequately powered randomized studies. Here, we discuss our experience using set guidelines to control blood glucose levels during childbirth. The methods are customized based on the kind of diabetes that the patient had prior to pregnancy, blood glucose control before birth, and diabetic treatment [36]. The general view is that maternal or fetal problems should be taken into consideration when determining the mode and time of delivery. Pregnancies in which fetal growth is normal should generally be allowed to continue until 41 weeks of gestation if glycemic control is only controlled through diet. Induced pregnancies should occur no later than 39–40 weeks of gestation in medically managed circumstances without consequences for the mother or the fetus. Fetal macrosomia or poorly managed maternal diabetes are reasons to induce labor at 38 weeks of gestation sooner than usual. Mothers should be made aware of the hazards associated with vaginal birth as opposed to elective abdominal delivery in cases of fetal macrosomia.

Neonatal Care:

Neonatal hypoglycemia, which is characterized by a capillary glucose level of less than 45 mg/dL (2.5 mmol/l), may occur even with strict glycemic management during delivery. Pregnancy-related hyperplasia of the fetal pancreas can be caused by poorly managed diabetes, which can cause persistent hyperinsulinemia in the first few months of life. The current guidelines place a strong emphasis on the necessity of strict glucose monitoring and early feeding in order to avoid hypoglycemia. Within the first thirty minutes of life and then every two to three hours after that, infants should be fed with the goal of maintaining a >35 mg/dL (2 mmol/L) of prefeed capillary glucose at four consecutive glucose tests. Infants who do not acquire hyperglycemic during the peak feeding assistance period should be assessed for enteral tube feeding or intravenous glucose infusion.37Patients with GDM or type 2 DM who are on a diet or who require less than 0.5 u/kg/d are monitored using a simple capillary glucose monitor every one to two hours, unless the glucose level is consistently above 6.5 mmol/L. For women with GDM or type 2 diabetes who need ≥0.5 u/kg/d of insulin, an IV of 10% dextrose in water is started with a piggybacked insulin infusion. Every hour, the capillary glucose is measured, and the insulin infusion is modified to react to variations in the blood sugar level, with a goal of 4.1–6.0 mmol/L. The glucose infusion is changed if necessary. This strategy differs significantly from many other methods in that if the glucose falls sharply, the insulin Infusion is stopped right away. The insulin infusion is discontinued at delivery. After giving birth, women with type 2 diabetes are closely watched and given insulin or oral hypoglycemic medications as needed. Postpartum women with GDM have their blood sugar checked once the next day. Unless it is a post-csection birth, in which case the IV insulin glucose regimen is continued with higher target glucose levels and subcutaneous insulin begun when food intake is resumed, patients with type 1 diabetes are restarted on 90% of their pre-pregnancy sub-cutaneous insulin dose.

Postpartum Care:

For women with a history of gestational diabetes mellitus, lifestyle modifications can be quite successful in preventing diabetes [37]. Historically, pregnancy and the postpartum period have been the times when lifestyle therapies for women with GDM have been offered. Pregnancy-related lifestyle changes have been shown to enhance glucose management and lessen the risk of adverse perinatal outcomes for both moms and babies.38 Postpartum lifestyle treatments were linked to a 43% reduction in the long-term risk of type 2 diabetes and diabetes-related risk variables (such as insulin resistance [39] and weight loss) [40].

Researchers found difficulties in offering even though these therapies are helpful in enhancing health outcomes during the postpartum period, postpartum-only lifestyle interventions are not recommended for women with histories of GDM in clinical practice. For instance, following the rigorous treatment and control of gestational diabetes mellitus during pregnancy, postpartum GDM mothers reported feeling abandoned [41]. For women with GDM, lifestyle modifications throughout pregnancy and the postpartum period show significant benefits. First, as the rate at which T2D develops is fastest between three to six years of the index pregnancy, the first few years following the index pregnancy with GDM may be the most beneficial for preventing T2D [42]. Second, it is best to avoid putting less emphasis on leading a healthy lifestyle throughout

pregnancy and the postpartum phase. According to research, programs initiated after six months of pregnancy are less beneficial than those initiated earlier when it comes to lifestyle modifications [43]. Throughout pregnancy and the postpartum period, continuous treatment for women with or at high risk for GDM through lifestyle intervention programs may be a potentially effective strategy to avoid T2D. In order to prevent type 2 diabetes, the objectives of this review were to investigate the features and efficacy of lifestyle treatments for GDM during pregnancy and the postpartum phase.

Instead of viewing a pregnancy complicated by GDM as a disastrous occurrence for the mother's and her unborn child's metabolism, one could view it as an opportunity to enhance the mother's health for future pregnancies. Consequently, the first few postpartum months should be dedicated to implementing lifestyle changes and follow-up care. Everyone agrees that altering one's lifestyle reduces the chance of developing diabetes in the future. A nutritious diet and graded physical exercise that returns BMI to normal is the first step in preventing diabetes in the future. To lose 0.5–1 kg of weight per week, GDM moms should follow a postpartum diet with an energy deficit of 500–1000 calories per day. 30 minutes of graded exercise five days a week is highly recommended. It's also advised to combine strength training with small weights and elastic bands with aerobic activities like swimming, yoga, and brisk walking.

SUMMERY

The most frequent pregnancy-related problem is diabetes. Pregestational planning is essential for all women who have diabetes at baseline. At the initial prenatal appointment, pregnant women without a known diabetes but with any risk factors for gestational diabetes should be evaluated with a 75-g OGTT; by 28 weeks gestation, all women should have had screening. Clinicians should create a comprehensive and effective outpatient management paradigm in anticipation of a rise in the number of pregnant women diagnosed with diabetes. The cornerstone of effectively managing diabetes during pregnancy is patient education. Normoglycemia before, during, and after all pregnancies complicated by diabetes will remain the aim of care.

Future Advancement:

Innovations in medical science and technology could eventually result in novel methods, including precision medicine, for treating newborns born to moms with gestational diabetes mellitus (GDM). More proactive and focused therapies may result from research into early biomarkers that predict the risk of problems in neonates born to moms with GDM. It may be possible to maximize growth and development results by looking further into specialized nutritional therapies for newborns that take into account their exposure to GDM in utero. Technological developments in telehealth and remote monitoring may make follow-up treatment for newborns easier to get and more frequent, particularly for those who reside in underserved or remote places. Investigating gene therapy and epigenetic changes may present new avenues for reducing the long-term impact of GDM exposure on the health of newborns. Optimizing maternal health measures during pregnancy to target gestational diabetes mellitus (GDM) at its source may have a significant effect on the health of the fetus. It's critical to remember that these are only theoretical recommendations, and that actual research and clinical practice directions will be determined by continuing investigations and developments in the field of medicine improved care for neonates born to moms with GDM requires close collaboration between researchers, physicians, and other stakeholders. New discoveries must be translated into action.

REFERENCES

1. Alberti, K. G. M. M., & Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabetic medicine*, *15*(7), 539-553.
2. Bennewitz, H. G. (1824). *De diabete mellito, graviditatis symptomate* (Doctoral dissertation, Typis Ioannis Friderici Starckii).
3. Hadden, D. R. (2010). Historical context of hyperglycemia in pregnancy. *A Practical Manual of Diabetes in Pregnancy*, 35-44.
4. Koivunen, S., Viljakainen, M., Männistö, T., Gissler, M., Pouta, A., Kaaja, R., ... & Vääräsmäki, M. (2020). Pregnancy outcomes according to the definition of gestational diabetes. *PLoS One*, *15*(3), e0229496.
5. Halbritter, S., Fedrigo, M., Höllriegl, V., Szymczak, W., Maier, J. M., Ziegler, A. G., & Hummel, M. (2012). Human breath gas analysis in the screening of gestational diabetes mellitus. *Diabetes technology & therapeutics*, *14*(10), 917-925.
6. Barbour, L. A., McCurdy, C. E., Hernandez, T. L., Kirwan, J. P., Catalano, P. M., & Friedman, J. E. (2007). Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. *Diabetes care*, *30*(Supplement_2), S112-S119.
7. Genevay, M., Pontes, H., & Meda, P. (2010). Beta cell adaptation in pregnancy: a major difference between humans and rodents? *Diabetologia*, *53*, 2089-2092.
8. Xiong, X., Saunders, L. D., Wang, F. L., & Demianczuk, N. N. (2001). Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. *International Journal of Gynecology & Obstetrics*, *75*(3), 221-228.
9. Nguyen, C. L., Pham, N. M., Binns, C. W., Duong, D. V., & Lee, A. H. (2018). Prevalence of gestational diabetes mellitus in eastern and southeastern Asia: a systematic review and meta-analysis. *Journal of diabetes research*, *2018*.

10. Ferrara, A. (2007). Increasing prevalence of gestational diabetes mellitus: a public health perspective. *Diabetes care*, *30*, S141.
11. Adams, S., & Rheeder, P. (2017). Screening for gestational diabetes mellitus in a South African population: Prevalence, comparison of diagnostic criteria and the role of risk factors. *South African medical journal*, *107*(6), 523-527.
12. Lin, P. C., Hung, C. H., Chan, T. F., Lin, K. C., Hsu, Y. Y., & Tzeng, Y. L. (2016). The risk factors for gestational diabetes mellitus: A retrospective study. *Midwifery*, *42*, 16-20.
13. Ferrara, A. (2007). Increasing prevalence of gestational diabetes mellitus: a public health perspective. *Diabetes care*, *30*, S141.
14. Federation, I. D. (2017). IDF diabetes atlas 8th edition. *International diabetes federation*, 905-911.
15. Handwerger, S., & Freemark, M. (2000). The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development. *Journal of Pediatric Endocrinology and Metabolism*, *13*(4), 343-356.
16. Shen, Y., Jia, Y., Zhou, J., Cheng, X. Y., Huang, H. Y., Sun, C. Q., ... & Jiang, L. Y. (2020). Association of gestational diabetes mellitus with adverse pregnancy outcomes: our experience and meta-analysis. *International Journal of Diabetes in Developing Countries*, *40*, 357-370.
17. Hiersch, L., Berger, H., Okby, R., Ray, J. G., Geary, M., McDonald, S. D., ... & Melamed, N. (2019). Gestational diabetes mellitus is associated with adverse outcomes in twin pregnancies. *American journal of obstetrics and gynecology*, *220*(1), 102-e1.
18. Shen, Y., Jia, Y., Zhou, J., Cheng, X. Y., Huang, H. Y., Sun, C. Q., ... & Jiang, L. Y. (2020). Association of gestational diabetes mellitus with adverse pregnancy outcomes: our experience and meta-analysis. *International Journal of Diabetes in Developing Countries*, *40*, 357-370.
19. Desoye, G., Schweditsch, M. O., Pfeiffer, K. P., Zechner, R., & Kostner, G. M. (1987). Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. *The Journal of Clinical Endocrinology & Metabolism*, *64*(4), 704-712.
20. Law, K. P., & Zhang, H. (2017). The pathogenesis and pathophysiology of gestational diabetes mellitus: Deductions from a three-part longitudinal metabolomics study in China. *Clinica Chimica Acta*, *468*, 60-70.
21. Bagias, C., Xiarchou, A., & Saravanan, P. (2021). Screening, diagnosis, and management of GDM: An update. *Journal of Diabetology*, *12*(Suppl 1), S43-S51.
22. Kulshrestha, V., & Agarwal, N. (2016). Maternal complications in pregnancy with diabetes. JPMA. *The Journal of the Pakistan Medical Association*, *66*(9 Suppl 1), S74-7.
23. Casey, B. M., Lucas, M. J., McIntire, D. D., & Leveno, K. J. (1997). Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. *Obstetrics & Gynecology*, *90*(6), 869-873.
24. Bellamy, L., Casas, J. P., Hingorani, A. D., & Williams, D. (2009). Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *The Lancet*, *373*(9677), 1773-1779.
25. Hosamane, U. S., Malhotra, S., Narang, A., & Dhall, K. (1990). Perinatal outcome in relation to maternal glycaemic control in diabetic mothers. *The Indian Journal of Medical Research*, *92*, 216-219.
26. Ornoy, A. (2011). Prenatal origin of obesity and their complications: Gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. *Reproductive toxicology*, *32*(2), 205-212.
27. Scholtens, D. M., Kuang, A., Lowe, L. P., Hamilton, J., Lawrence, J. M., Lebenthal, Y., ... & Metzger, B. E. (2019). Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): maternal glycemia and childhood glucose metabolism. *Diabetes care*, *42*(3), 381-392.
28. Bhavadharini, B., Mahalakshmi, M. M., Anjana, R. M., Maheswari, K., Uma, R., Deepa, M., ... & Mohan, V. (2016). Prevalence of gestational diabetes mellitus in urban and rural Tamil Nadu using IADPSG and WHO 1999 criteria (WINGS 6). *Clinical diabetes and endocrinology*, *2*(1), 1-11.
29. Desoye, G., Schweditsch, M. O., Pfeiffer, K. P., Zechner, R., & Kostner, G. M. (1987). Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. *The Journal of Clinical Endocrinology & Metabolism*, *64*(4), 704-712.
30. Law, K. P., & Zhang, H. (2017). The pathogenesis and pathophysiology of gestational diabetes mellitus: Deductions from a three-part longitudinal metabolomics study in China. *Clinica Chimica Acta*, *468*, 60-70.1
31. Bagias, C., Xiarchou, A., & Saravanan, P. (2021). Screening, diagnosis, and management of GDM: An update. *Journal of Diabetology*, *12*(Suppl 1), S43-S51.
32. Abbott, D. H., Rogers, J., Dumesic, D. A., & Levine, J. E. (2019). Naturally occurring and experimentally induced rhesus macaque models for polycystic ovary syndrome: translational gateways to clinical application. *Medical Sciences*, *7*(12), 107.
33. Balsells, M., García-Patterson, A., Solà, I., Roqué, M., Gich, I., & Corcoy, R. (2015). Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. *Bmj*, *350*.
34. Rosenstein, M. G., Cheng, Y. W., Snowden, J. M., Nicholson, J. M., & Caughey, A. B. (2012). Risk of stillbirth and infant death stratified by gestational age. *Obstetrics and gynecology*, *120*(1), 76.
35. Kreiner, A., Gil, K., & Lavin, J. (2012). The effect of antenatal corticosteroids on maternal serum glucose in women with diabetes.
36. American College of Obstetricians and Gynecologists. (2005). ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists, Number 69, December 2005 (replaces Practice Bulletin Number 25, March

2001). Emergency contraception. *Obstet Gynecol*, *106*(6), 1443-1452.

37. Aroda, V. R., Christophi, C. A., Edelstein, S. L., Zhang, P., Herman, W. H., Barrett-Connor, E., ... & Diabetes Prevention Program Research Group. (2015). The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. *The Journal of Clinical Endocrinology & Metabolism*, *100*(4), 1646-1653.
38. Yamamoto, J. M., Kellett, J. E., Balsells, M., García-Patterson, A., Hadar, E., Solà, I., ... & Murphy, H. M. Gestational Diabetes mellitus (GDM) and Diet: A systematic review and meta-analysis of randomized controlled trials examining the impact of modified dietary interventions on maternal glucose control and neonatal birthweight.
39. Goveia, P., Cañon-Montañez, W., Santos, D. D. P., Lopes, G. W., Ma, R. C., Duncan, B. B., ... & Schmidt, M. I. (2018). Lifestyle intervention for the prevention of diabetes in women with previous gestational diabetes mellitus: a systematic review and meta-analysis. *Frontiers in endocrinology*, *9*, 583.
40. Li, N., Yang, Y., Cui, D., Li, C., Ma, R. C., Li, J., & Yang, X. (2021). Effects of lifestyle intervention on long-term risk of diabetes in women with prior gestational diabetes: A systematic review and meta-analysis of randomized controlled trials. *Obesity Reviews*, *22*(1), e13122.
41. Van Ryswyk, E., Middleton, P., Shute, E., Hague, W., & Crowther, C. (2015). Women's views and knowledge regarding healthcare seeking for gestational diabetes in the postpartum period: a systematic review of qualitative/survey studies. *Diabetes research and clinical practice*, *110*(2), 109-122.
42. Song, C., Lyu, Y., Li, C., Liu, P., Li, J., Ma, R. C., & Yang, X. J. O. R. (2018). Long-term risk of diabetes in women at varying durations after gestational diabetes: a systematic review and meta-analysis with more than 2 million women. *Obesity reviews*, *19*(3), 421-429.
43. Goveia, P., Cañon-Montañez, W., Santos, D. D. P., Lopes, G. W., Ma, R. C., Duncan, B. B., ... & Schmidt, M. I. (2018). Lifestyle intervention for the prevention of diabetes in women with previous gestational diabetes mellitus: a systematic review and meta-analysis. *Frontiers in endocrinology*, *9*, 583.